What type of study is this?

This is a Systematic Review study.

December 8, 2025BloodOpen Access

Assessing patient-reported outcomes in Phase 3 multiple myeloma trials between 2020-2024 – a systematic review.

View Full Paper

Ask AI

Bookmark

Authors

NANawaraj AdhikariStaten Island University Hospital UBUjwal BasnetStaten Island University Hospital

Discussion

Member takes

Implication

Systematic review assesses patient-reported outcomes in multiple myeloma clinical trials, highlighting inconsistent reporting practices and need for standardized guidelines.

Key Points

The review identified that 71% of phase 3 clinical trials included patient-reported outcomes as secondary endpoints.
Only a small number of trials reported significant differences in quality of life between the intervention and control arms.
The analysis utilized Covidence software to systematically assess the selection criteria and reporting of patient-reported outcomes.
Findings indicate a pressing need for reporting guidelines to improve consistency in quality of life data across trials.

Cite This Study

Adhikari et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7e1 https://doi.org/10.1182/blood-2025-2822

View Full Paper

Ask AI

Bookmark

Implication

Systematic review assesses patient-reported outcomes in multiple myeloma clinical trials, highlighting inconsistent reporting practices and need for standardized guidelines.

Assessing patient-reported outcomes in Phase 3 multiple myeloma trials between 2020-2024 – a systematic review.

Discussion

Member takes

Implication

Key Points

Cite This Study

Assessing patient-reported outcomes in Phase 3 multiple myeloma trials between 2020-2024 – a systematic review.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider